1991
DOI: 10.1016/0378-5122(91)90199-z
|View full text |Cite
|
Sign up to set email alerts
|

Org OD 14 and the endometrium

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
30
2
4

Year Published

1994
1994
2017
2017

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 109 publications
(37 citation statements)
references
References 13 publications
1
30
2
4
Order By: Relevance
“…Histological studies following treatment with tibolone for 3 months or longer revealed that the endometrium becomes atrophic, suggesting a progestagenic inhibition or lack of estrogenic stimulation of endometrial cell proliferation 3,4 . In the laboratory, the progestagenic effects of tibolone on the endometrium have been demonstrated by measuring various progesterone-regulated factors.…”
Section: Discussionmentioning
confidence: 99%
“…Histological studies following treatment with tibolone for 3 months or longer revealed that the endometrium becomes atrophic, suggesting a progestagenic inhibition or lack of estrogenic stimulation of endometrial cell proliferation 3,4 . In the laboratory, the progestagenic effects of tibolone on the endometrium have been demonstrated by measuring various progesterone-regulated factors.…”
Section: Discussionmentioning
confidence: 99%
“…13,14,19 Tibolone (Org OD14), a synthetic steroid [(7␣,17␣)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one] with a combination of estrogenic, androgenic, and progestogenic properties, is clinically effective for the treatment of climacteric symptoms 39,40 and the treatment and prevention of osteoporosis in postmenopausal women, 41 with no stimulatory effect on the endometrium. 42,43 The effect on the development of atherosclerosis is not known. It has been suggested that tibolone might have less atheroprotective effect than ERT because of its progestogenic/androgenic properties.…”
mentioning
confidence: 99%
“…The ␦-4 isomer, produced primarily within the endometrium, protects the endometrium from the agonist effects of the 2 estrogenic metabolites. 13,14 Tibolone treatment of postmenopausal women has some beneficial effects on plasma lipid/lipoprotein concentrations (reductions in plasma triglyceride 15,16 and lipoprotein[a] concentrations) 17 ; however, concern has arisen about its "cardiovascular safety" because of reductions in HDLC. 15,18 We have reported the long-term effects of tibolone on coronary artery atherosclerosis of surgically postmenopausal cynomolgus monkeys relative to the effects of conjugated equine estrogen (CEE) treatment and treatment with CEE plus medroxyprogesterone (MPA) administered continuously.…”
mentioning
confidence: 99%